NCT01516749

Anakinra as a Treatment for Hydradenitis Suppurativa

An Open Label Non-randomized Study Assessing the Efficacy and Tolerability of Fixed-dose Regimen Daily Subcutaneous Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: University of California, San Francisco · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, proof-of-concept research study to assess the effectiveness of anakinra in the treatment of patients with hidradenitis suppurativa (HS). The planned intervention is to provide about 6 HS patients with anakinra 100mg daily injections to administer subcutaneously for 8 weeks. Then, the study subjects will be followed for a further 8 weeks to monitor for relapse of HS.

Conditions

• Hidradenitis Suppurativa

Interventions

Type	Name	Description
DRUG	anakinra	Anakinra is supplied in individual pre-filled glass syringes 100mg/0.67mL each. It will be injected subcutaneously once daily for 8 continuous weeks.

Timeline

• Start date: 2012-10-01
• Primary completion: 2013-05-01
• Completion: 2013-07-01
• First posted: 2012-01-25
• Last updated: 2014-08-20
• Results posted: 2014-08-06

Locations

1 site across 1 country: United States